Holen Sie sich die Stockscreener-App
0.2106
0.57%
-0.0012
Vorhandelsmarkt:
.20
-0.0106
-5.03%
Schlusskurs vom Vortag:
$0.2118
Offen:
$0.2118
24-Stunden-Volumen:
723.84K
Relative Volume:
0.54
Marktkapitalisierung:
$6.14M
Einnahmen:
$1,000
Nettoeinkommen (Verlust:
$-14.08M
KGV:
-0.1907
EPS:
-1.1043
Netto-Cashflow:
$-7.05M
1W Leistung:
-28.37%
1M Leistung:
-28.12%
6M Leistung:
-81.20%
1J Leistung:
-94.27%
1-Tages-Spanne:
$0.201
$0.2151
1-Wochen-Bereich:
$0.201
$0.2917
52-Wochen-Spanne:
$0.201
$4.0185
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
Firmenname
Ernexa Therapeutics Inc
Sektor
Branche
Telefon
(617) 798-6700
Adresse
1035 CAMBRIDGE STREET, CAMBRIDGE
Compare ERNA vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
0.2106 | 6.14M | 1,000 | -14.08M | -7.05M | -1.1043 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Ernexa Therapeutics Inc Aktie (ERNA) Neueste Nachrichten
Eterna Therapeutics Faces Nasdaq Delisting Risk After Notice - The Globe and Mail
Ernexa Therapeutics Inc. Files Form 8-K: Notice of Nasdaq Delisting and Company Response – March 2026 - Minichart
Ernexa Therapeutics receives Nasdaq delisting notice due to minimum bid price By Investing.com - Investing.com India
Ernexa Therapeutics receives Nasdaq delisting notice due to minimum bid price - Investing.com Australia
Ernexa Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Resistance Check: Is PAVmed Inc stock a value trap2026 Key Lessons & Precise Buy Zone Tips - baoquankhu1.vn
AI Stocks: Why is Ernexa Therapeutics Inc stock going upTrade Risk Report & High Conviction Buy Zone Alerts - baoquankhu1.vn
Ernexa Therapeutics Inc may offer up to $50 million of securitiesSEC filing - marketscreener.com
Ernexa Therapeutics IncMay Offer Up To $50 Million Of SecuritiesSEC Filing - TradingView
Ernexa Therapeutics Inc. 2025 Annual Report: Synthetic Allogeneic iMSC Therapy, Business Overview, Key Risks, and Patent Portfolio - Minichart
Ernexa Therapeutics 2025 10-K: $0.0M Revenue, Net Loss $(14.08)M - TradingView
Ernexa Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Aug Wrap: Is Ernexa Therapeutics Inc exposed to currency risksPortfolio Growth Summary & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Ernexa Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Aug Sentiment: What is Ernexa Therapeutics Incs book value per shareJuly 2025 Price Swings & Accurate Entry/Exit Alerts - baoquankhu1.vn
Breakout Move: Is Ernexa Therapeutics Inc a strong candidate for buy and holdJuly 2025 Institutional & Pattern Based Trade Signal System - baoquankhu1.vn
Ernexa Therapeutics Inc.Common Stock (NQ: ERNA - FinancialContent
Comparing Aditxt (NASDAQ:ADTX) & Ernexa Therapeutics (NASDAQ:ERNA) - Defense World
ERNA Technical Analysis & Stock Price Forecast - Intellectia AI
Eterna Therapeutics Updates Investor Presentation, Highlights Web Disclosure - The Globe and Mail
Ernexa Therapeutics updates investor presentation, posts Exhibit 99.1 on website - TradingView
Ernexa Therapeutics (NASDAQ: ERNA) furnishes new February 2026 investor presentation - Stock Titan
Ernexa Therapeutics (NASDAQ:ERNA) Trading Down 11.4% – Time to Sell? - Defense World
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series - GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Will Ernexa Therapeutics Inc. stock outperform value stocksQuarterly Growth Report & Fast Moving Stock Watchlists - mfd.ru
Insider Stock Purchases: February 18, 2026 - Quiver Quantitative
Ernexa therapeutics ten percent owner Cherington buys $2m in stock By Investing.com - Investing.com India
Ernexa therapeutics ten percent owner Cherington buys $2m in stock - Investing.com
Ernexa Therapeutics 10% Owner Acquires 4 Million Shares - TradingView
ERNA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Will Ernexa Therapeutics Inc. outperform tech stocksJuly 2025 Chart Watch & Accurate Buy Signal Notifications - mfd.ru
Can Ernexa Therapeutics Inc. continue delivering strong returnsQuarterly Trade Review & Capital Efficiency Focused Strategies - mfd.ru
Will Ernexa Therapeutics Inc. stock remain a Wall Street favoriteWeekly Market Outlook & Short-Term High Return Ideas - mfd.ru
Will Ernexa Therapeutics Inc. stock benefit from green energy trendsTrade Volume Summary & Accurate Buy Signal Notifications - mfd.ru
Eterna Therapeutics Completes Public Offering to Bolster Capital - TipRanks
Ernexa Therapeutics Signs Multiple Financing Agreements - TradingView
Profit Review: Can Ernexa Therapeutics Inc. be recession proofWeekly Gains Report & Daily Momentum Trading Reports - mfd.ru
What hedge fund activity signals for Ernexa Therapeutics Inc. stockJuly 2025 PostEarnings & Target Return Focused Picks - mfd.ru
Total debt of Ernexa Therapeutics Inc. – NASDAQ:ERNAW - TradingView
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Ernexa Therapeutics prices $10.5 million public offering at $0.50 per share - Investing.com
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering - The Manila Times
Ernexa Therapeutics Inc. Announces Pricing of $10.5 Million Public Offering of Common Stock and Warrants - Quiver Quantitative
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Street Watch: Is Ernexa Therapeutics Inc forming bullish engulfing patternsQuarterly Investment Review & Reliable Entry Point Alerts - baoquankhu1.vn
Valuation Update: Why is Ernexa Therapeutics Inc stock going up2025 Volume Leaders & Proven Capital Preservation Methods - baoquankhu1.vn
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Ernexa Therapeutics Advances toward First-in-Human Trial for Ovarian Cancer Following Successful Pre-IND Meeting with FDA - Quiver Quantitative
Ernexa Therapeutics Participates in Virtual Investor “What - GlobeNewswire
Japanese trade program selects Ernexa Therapeutics among elite biotech group - Investing.com Canada
Finanzdaten der Ernexa Therapeutics Inc-Aktie (ERNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):